Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.64 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.43 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16163564 | 0.87 | PI4KB (0.61) | PI4KBMEN1KMT2APOLBALDH1A1 | |
| SCHEMBL653167 | 0.83 | PI4KB (0.75) | PI4KBMEN1KMT2APOLBALDH1A1 | |
| SCHEMBL16163944 | 0.83 | PI4KB (0.49) | PI4KBMEN1KMT2AALDH1A1TSHR | |
| SCHEMBL653839 | 0.82 | PI4KB (0.61) | PI4KBPOLBALDH1A1LMNAMAPK1 | |
| SCHEMBL16163549 | 0.79 | ATM (0.51) | PI4KBMEN1KMT2AALDH1A1ATM | |
| SCHEMBL654617 | 0.79 | PI4KB (0.66) | PI4KBMEN1KMT2APOLBALDH1A1 | |
| SCHEMBL4113637 | 0.79 | PI4KB (0.63) | PI4KBMEN1KMT2APOLBALDH1A1 | |
| SCHEMBL652600 | 0.78 | PI4KB (0.73) | PI4KBMEN1KMT2APOLBALDH1A1 | |
| SCHEMBL17964820 | 0.78 | PI4KB (1.00) | PI4KBPOLBENPP2MAPTHPGD | |
| SCHEMBL16163926 | 0.78 | SMN1; SMN2 (0.50) | MEN1KMT2AALDH1A1LMNAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9227984-B2 | Therapeutically active fused pyrimidine derivatives | UCB PHARMA S.A. (BE) | 2016-01-05 | — | — | US | disclosed |
| US-20140309222-A1 | Therapeutically Active Fused Pyrimidine Derivatives | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2014-10-16 | — | — | US | disclosed |
| EP-2616077-A1 | ANTI-CANCER ACTIVITY OF NOVEL BICYCLIC HETEROCYCLES | Katholieke Universiteit Leuven, K.U. Leuven R&D (BE) | 2013-07-24 | — | — | EP | disclosed |
| WO-2012035423-A1 | ANTI-CANCER ACTIVITY OF NOVEL BICYCLIC HETEROCYCLES | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140309222-A1 | Therapeutically Active Fused Pyrimidine Derivatives | HAVCR2, TPMT, PAICS | PI4KB 293/4885MEN1 3860/4885KMT2A 2462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.